Terms ending in 2038
Every in-force patent on Hemanext Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,898,517 | Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood In force · Medium confidence | Hemanext Inc. | In force | Medium confidence | |
| US 11,026,970 | Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood In force · High confidence | Hemanext Inc. | In force | High confidence | |
| US 11,026,971 | Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood In force · Low confidence | Hemanext Inc. | In force | Low confidence | |
| US 11,033,581 | Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood In force · Medium confidence | Hemanext Inc. | In force | Medium confidence | |
| US 11,052,110 | Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood In force · Low confidence | Hemanext Inc. | In force | Low confidence | |
| US 12,582,674 | Methods and Treatment of Trauma In force · High confidence | Hemanext Inc. | In force | High confidence | |
| US 11,576,931 | Methods and Treatment of Trauma Adverse Events with Oxygen Reduced Blood In force · Medium confidence | Hemanext Inc. | In force | Medium confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.